EGFR is overexpressed in a range of epithelial tumor types, and somatic mutations in EGFR were found to mediate the susceptibility of non-small cell lung cancer to gefitinib, a chemotherapeutic that inhibits the kinase activity of EGFR (Lynch et al. This evidence concerns the gene EGFR and non-small cell lung carcinoma.